Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?
Acta Medica (Hradec Kralove, Czech Republic) · 2025 · 68 (4) · 113-122
DOI: 10.14712/18059694.2026.1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Medica (Hradec Kralove, Czech Republic), online erschienen am 24.03.2026. Verfasst von Martin Šimkovič und 3 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine, University Hospital Hradec Králové, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, C…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
Over the past decade, chronic lymphocytic leukemia (CLL) management has undergone a fundamental transformation driven by the introduction of oral targeted inhibitors. Continuous Bruton tyrosine kinase (BTK) inhibition and time-limited BCL-2–based therapy has replaced chemoimmunotherapy as the standard of care, improving survival and quality of life. Ibrutinib and its next-generation analogues, acalabrutinib and zanubrutinib, provide durable disease control with improved safety. At the same time, venetoclax combined with anti-CD20 antibodies enables deep and measurable residual disease (MRD)-negative remissions within fixed-duration regimens. Recent trials have demonstrated the feasibility of MRD-guided treatment cessation and the potential benefit of combining BTK and BCL-2 inhibition to achieve durable, chemotherapy-free responses. Ongoing research focuses on optimizing treatment sequencing, overcoming acquired resistance through non-covalent BTK inhibitors, and integrating immunotherapeutic modalities such as bispecific antibodies and CAR-T cells. The current paradigm emphasizes individualized, biomarker- and comorbidity-driven therapy based primarily on TP53 and IGHV status, with treatment selection tailored to patient fitness, tolerance, and long-term safety. This review summarizes contemporary evidence, clinical practice recommendations, and future directions in the targeted management of CLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 4th Department of Internal Medicine, University Hospital Hradec Králové, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic. simkovicm@lfhk.cuni.cz.
- 4th Department of Internal Medicine, University Hospital Hradec Králové, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Šimkovič, M., Vejražková, E., Écsiová, D., & Vodárek, P. (2025). Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?. Acta Medica (Hradec Kralove, Czech Republic), 68(4), 113-122. https://doi.org/10.14712/18059694.2026.1
Vancouver
Šimkovič M, Vejražková E, Écsiová D, Vodárek P. Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?. Acta Medica (Hradec Kralove, Czech Republic). 2025;68(4):113-122. doi:10.14712/18059694.2026.1
BibTeX
@article{imkovi2025,
author = {Šimkovič, Martin and Vejražková, Eva and Écsiová, Dominika and Vodárek, Pavel},
title = {Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?},
journal = {Acta Medica (Hradec Kralove, Czech Republic)},
year = {2025},
volume = {68},
number = {4},
pages = {113--122},
doi = {10.14712/18059694.2026.1}
}
EUVIMED